导师风采
周爱萍

个人信息

Personal Information

  • 性别:女
  • 导师类型:博士生导师
  • 职称:主任医师
  • 该职称任职时间:20130901

联系方式

Contact Information

  • 所属院系:肿瘤医院
  • 所属专业:
  • 邮箱 : zhouap1825@126.com
  • 工作电话 : 87788208

个人简介

Personal Profile

周爱萍,女,中国医学科学院肿瘤医院内科主任医师,博士生导师 一、 教育经历 1996.9- 2001.7 中国协和医科大学肿瘤学专业 硕博连读研究生 医学博士学位 1988.9-1993.7 北京医科大学 临床医学系 医学学士学位 二、 工作和任职经历 2013.9- 中国医学科学院肿瘤医院内科 主任医师 2005.9- 2013.8 中国医学科学院肿瘤医院内科 副主任医师 2001.9- 2005.9 中国医学科学院肿瘤医院内科 主治医师 1999.9- 2002.2 协和医院 内科进修 1993.9~1996.7 中国医学科学院肿瘤医院 内科 住院医师 三、工作特长 自1993年开始从事肿瘤内科工作,擅长结直肠癌、胃癌、食管癌、肝胆胰等消化道肿瘤和肾癌、膀胱癌等泌尿肿瘤的化疗、生物靶向及免疫治疗。有丰富的抗癌新药临床研究经验。担任《CSCO结直肠癌诊治指南》共同执笔人、《CSCO肾癌诊治指南》、《CSCO胃癌诊治指南》、《CSCO尿路上皮癌诊治指南》专家组成员。 四、学术兼职 中国临床肿瘤学会(CSCO)理事, 中国临床肿瘤学会(CSCO)尿路上皮癌专业委员会副主任委员,中国临床肿瘤学会(CSCO)结直肠癌/胃癌/智慧医疗专业委员会常务委员,中国临床肿瘤学会(CSCO)肾癌专业委员会委员兼秘书,中国医药教育协会腹部肿瘤结直肠癌分会副主任委员,中国老年学会老年肿瘤专业委员会副干事长、消化道肿瘤分会副主任委员,中国研究型医院精准医学与肿瘤MDT专业委员会副主任委员,中国医疗保健国际交流促进会消化道肿瘤MDT分委会副主任委员,中国医疗保健国际交流促进会结直肠癌肝转移治疗专业委员会/神经内分泌肿瘤专业委员会常务委员,中国抗癌协会胃癌专业委员会委员,中国抗癌协会抗癌药物专业委员会委员,中华医学会胰腺癌专业委员会委员,《中华肝胆外科杂志》编委,《中华临床医师杂志》编委,《中国继续教育杂志》编委,《肝癌电子杂志》编委,《中国新药杂志》,通讯编委《中华肿瘤杂志》审稿人。

团队简介

Team Profile

周爱萍导师团队主要从事消化系统肿瘤、泌尿系统肿瘤的基础与临床研究。目前,团队拥有主任医师5人,副主任医师1人,其中博士研究生导师3人。 课题组自成立以来,发扬 “尊科学济人道”的协和精神,学术研究把握肿瘤学理论前沿,在消化系统及泌尿系统肿瘤领域深入专研,不断创新。 学术研究方面:近年来,课题组近5年先后承担了中国医学科学院临床与转化医学研究专项(2023-12至2025-11):ctDNA 指导下TKI 联合PD-1 单抗用于标准治疗失败的晚期pMMR/MSS 结直肠癌的随机对照临床研究;中国医学科学院肿瘤医院重点学科基金项目(2022):菌群移植联合免疫检查点抑制剂与TKI治疗晚期结直肠癌的II期研究;国家自然科学基金(2022-01至2025-12):LncRNA DLGAP1-AS2/FAM3D/GM3调控轴介导食管鳞癌化疗耐药的机制研究;国家自然科学基金重点项目(2020-01至2024-12):食管有丝分裂灾难关键调控分子的作用机制及靶向抑制研究;国家重点研发项目(2021-12至2024-12):食管癌变动态演进机制及个体化精准诊疗体系构建研究;中国医学科学院医学与健康科技创新工程:环境因素引起的癌症的分子机理与靶标的发现(2019) 协同子课题;国家重大新药创制(2018-01至2020-12):1类抗癌新药曲沙他滨的临床研发和产业化研究。近五年科研总经费约335万元,以(共同)第一作者或(共同)通讯作者发表SCI/EI论文及核心期刊约40余篇。 学术兼职方面:现任中国临床肿瘤学会(CSCO)理事, 中国临床肿瘤学会(CSCO)尿路上皮癌专业委员会副主任委员,中国临床肿瘤学会(CSCO)结直肠癌/胃癌/智慧医疗专业委员会常务委员,中国临床肿瘤学会(CSCO)肾癌专业委员会委员兼秘书,中国医药教育协会腹部肿瘤结直肠癌分会副主任委员,中国老年学会老年肿瘤专业委员会副干事长、消化道肿瘤分会副主任委员,中国研究型医院精准医学与肿瘤MDT专业委员会副主任委员,中国医疗保健国际交流促进会消化道肿瘤MDT分委会副主任委员,中国医疗保健国际交流促进会结直肠癌肝转移治疗专业委员会/神经内分泌肿瘤专业委员会常务委员,中国抗癌协会胃癌专业委员会委员,中国抗癌协会抗癌药物专业委员会委员,中华医学会胰腺癌专业委员会委员,《中华肝胆外科杂志》编委,《中华临床医师杂志》编委,《中国继续教育杂志》编委,《肝癌电子杂志》编委,《中国新药杂志》,通讯编委《中华肿瘤杂志》审稿人。 学生培养方面:迄今为止,课题组已培养硕士7名,在读硕士2人,在读博士2人。 课题组在周爱萍老师的带领下,学术领域不断探索,临床能力不断精进。我们期待你的加入,共同学习,共同进步!

  • 研究方向Research Directions
消化系统、泌尿系统肿瘤的精准/免疫治疗和生物标志物、耐药机制研究,新药临床研发
  • 在校研究生Current Graduate Students

硕士研究生 2 名,博士研究生 2 名

  • 科研项目Research Projects
# 项目名称 起止日期 金额 项目类型 本人角色
1LncRNA DLGAP1-AS2/FAM3D/GM3调控轴介导食管鳞癌化疗耐药的研究机制2021-08-01 —— 55.0主持在研的国家或省部级科研项目主持者
2食管癌有丝分裂灾难关键调控分子的作用机制及靶向抑制研究2020-01-31 —— 297.0参与在研的国家或省部级科研项目参与者
3食管癌变动态演进机制及个体化精准诊疗体系构建研究2021-12 —— 2024-12450参与在研的国家或省部级科研项目骨干参与
  • 发表论文Papers
# 论文题目 期刊名称 发表年份 论文署名
1Serum concentration of CD137 and tumor infiltration by M1 macrophages predict the response to sintilimab plus bevacizumab biosimilar in advanced hepatocellular carcinoma patientsClinical Cancer Research2022-06-17周爱萍
2 Open-label, multicenter, phase 2 study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinomaClinical Cancer Research2022-06-17周爱萍
3治疗相关高血压与血管内皮生长因子受体酪氨酸激酶抑制剂治疗转移性肾细胞癌疗效的关系中华肿瘤杂志2022-06-17周爱萍
4Famitinib in metastatic renal cell carcinoma: a single center studyChinese Medical Journal (English)2022-06-17周爱萍
5NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy predictionPathology Research and Practice2022-06-17周爱萍
6Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective StudyCancer Management and Research2022-06-17周爱萍
7RECIST 1.1, Choi and mChoi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with Regorafenib and anti-PD-1 antibodyEuropean Journal of Radiology2022-06-17周爱萍
8Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cel lCarcinoma Treated by Targeted TherapyChinese Medical Journal (English)2022-06-17周爱萍
9抗血管生成酪氨酸激酶抑制剂治疗转移性肾细胞癌的手足皮肤反应与疗效的关系中华医学杂志2022-06-17周爱萍
10多西紫杉醇与替吉奥联合铂类治疗晚期胃癌的II期临床研究中华医学杂志2022-06-17周爱萍
11Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter surveyHPB (Oxford)2022-06-17周爱萍
12Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 TrialFrontiers Oncology2022-06-17周爱萍
13Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort studyAsia-Pacific Journal of Clinical Oncology2022-06-17周爱萍
14Comparison of 627 patients with right- and left-sided colon cancer in China: Differences in clinicopathology, recurrence, and survivalChronic Diseases and Translational Medicine2022-06-17周爱萍
15Changes in expression of multiple checkpoint molecules and infiltration of tumor immune cells after neoadjuvant chemotherapy in gastric cancerJournal of Cancer2022-06-17周爱萍
16Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)Hepatology International2022-06-17周爱萍
17Comparison of S-1 Plus Oxaliplatin (SOX) and Capecitabine Plus Oxaliplatin (XELOX) as Adjuvant Chemotherapies for Stage II and III Gastric Cancer After D2 Resection: A Single-Center Retrospective StudyAsia-Pacific Journal of Clinical Oncology2022-06-17周爱萍
18Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trialCancer Chemotherapy and Pharmacology2022-06-17周爱萍
19西妥昔单抗联合化疗一线治疗KRAS/RAS野生型转移性结直肠癌的疗效及预后因素分析癌症进展2022-06-17周爱萍
20A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinomaAsia-Pacific Journal of Clinical Oncology2022-06-17周爱萍
21Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical TrialOncologist2022-06-17周爱萍
22Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II StudyCancer Research and Treatment2022-06-17周爱萍
23Body mass index and age are additional prognostic factors in patients with metastatic renal cellcarcinoma treated with tyrosine kinase inhibitorsUrologic Oncology2022-06-17周爱萍
24Phase I study of the safety, pharmacokinetics and antitumor activity of famitinibCancer Chemotherapy and Pharmacology2022-06-17周爱萍
25替西罗莫司治疗转移性肾细胞癌初探癌症进展2022-06-17周爱萍
26Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysisHepatology2022-06-17周爱萍
27索拉非尼治疗转移性肾癌的临床研究中华泌尿杂志2022-06-17周爱萍
28 High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinomaFuture Oncology2022-06-17周爱萍
29Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trialHepatobiliary Surgery and Nutrition2022-06-17周爱萍
30Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert StatementsLiver Cancer2022-12周爱萍
31Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agentsClin Transl Oncol2022-12周爱萍
32Advanced development of biomarkers for immunotherapy in hepatocellular carcinomaFront Oncol2023-12周爱萍
33Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial: A randomized clinical trial of neoadjuvant therapy for ESCCBMC Med2023-12周爱萍
34Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patientsiScience2023-12周爱萍
35Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trialBMC Cancer2023-12周爱萍
36Abnormal generation of IL-17A represses tumor infiltration of stem-like exhausted CD8 T cells to demote the antitumor immunityBMC Med2023-12周爱萍
37Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitorsTher Adv Med Oncol2023-12周爱萍
38Neutrophil extracellular traps in relationship to efficacy of systemic therapy for metastatic renal cell carcinomaCancer Med2023-12周爱萍
39Efficacy and Safety of Disitamab Vedotin in Patients with Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical TrialsJ Clin Oncol2024-06周爱萍
40Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trialGastric Cancer2024-06周爱萍
41A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinomaCancer Immunol Immunother2024-06周爱萍
42Serum IgA as a Prognostic Beacon: Anticipating Systemic Therapy Efficacy in Metastatic Clear Cell Renal Cell CarcinomaAnn Surg Oncol2024-06周爱萍
43A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinomaEur J Cancer2024-06周爱萍
  • 科研获奖Research Awards


  • 研究成果Research Findings